I'm currently a PhD student at Newcastle University, specialising in the molecular basis of cancer. Specifically, I am interested in early genetic fusion events during prostate tumourigenesis with a strong emphasis on generating clinical models such as novel cell lines and 3D organoids that recapitulate the disease phenotype. Previously, I held a position as a Research Scientist at the Northern Institute for Cancer Research, where I was tightly involved in a multi-national project that acquired daily human tissue samples for processing and analysis. Additionally, I have gained experience in the design and execution of multiple experiments simultaneously, with a strong emphasis on biochemical assays such as BCA/ ELISA/ Luciferase assays along with DNA/ RNA isolation, protein quantification/ isolation and quantitative PCR. My research focus has shifted over the last few years. Initially, I explored the complex relationship of the TGFB pathway when influenced by the retrotransposon LINE1 and its encoded protein, L1orf1p. I have also been involved in a project that involves the Hepatitis C Virus and its interruption of the DNA damage response even after viral clearance.Due to my work on these projects, I have been published in two reputable journals. - HCV Activates Somatic L1 Retrotransposition—A Potential Hepatocarcinogenesis Pathway- Expression of retrotransposon protein L1orf1p activates TGFβ signalling in hepatocellular carcinoma via cytoplasmic Pin1 upregulationCore Skills: DNA/ RNA extraction, cDNA synthesis, genotyping, cloning, lipoparticle and lentiviral transfection, molecular cloning, target validation, drug screening, qPCR, mammalian cell culture, assay design, western blot, animal handling, dissection/ tissue processing, immunohistochemistry, immunofluorescence, confocal microscopy, protein quantification/ isolation, HPLC, spectrophotometry, GC, FACs, flow cytometry and RNA sequencing & analysis. Assays: Proliferation, migration, invasion, BCA, ELISA, cell viability, IC50Animal handling license - PIL AB Date acquired: 04/11/2021